Peptides for Infertility: Male & Female Fertility Research

Infertility affects approximately 1 in 7 couples in the UK, with roughly equal contributions from male and female factors. While assisted reproductive technologies (IVF, ICSI) remain the primary treatment pathway, peptide-based approaches — particularly those targeting the hypothalamic-pituitary-gonadal (HPG) axis — are increasingly researched for their role in restoring natural fertility mechanisms.

Kisspeptin, discovered in 2003 at the University of Cambridge, has emerged as a particularly promising peptide for fertility applications. It acts as the master regulator of the reproductive hormone cascade, stimulating GnRH neurons to trigger the release of FSH and LH — hormones essential for ovulation and sperm production.

Gonadorelin (synthetic GnRH) is already used in NHS fertility clinics as part of IVF protocols. Research now explores whether kisspeptin-based approaches could offer a more physiological stimulation of ovulation with lower risk of ovarian hyperstimulation syndrome (OHSS) — a serious complication of conventional fertility treatments.

All information is for educational purposes. Infertility requires specialist assessment at an NHS or HFEA-regulated fertility clinic.